Erytech Pharma SA has reported Phase 2 data for a new formulation of asparaginase, in combination with chemotherapy, showing the drug was safe and effective in older patients with acute lymphoblastic leukaemia (ALL) for whom no alternatives exist.
Wilex AG said that a Phase 2 proof-of-concept trial of its cancer therapy, Mesupron combined with capecitabine, was more effective than capecitabine alone in patients with HER2-receptor negative metastatic breast cancer.
The US Food and Drug Administration has approved a new combination vaccine for infants and children aged six weeks through 18 months for the prevention of two types of meningococcal disease and Haemophilus influenzae type b (Hib disease).
H. Lundbeck A/S has announced plans to restructure its commercial organisation in Europe with the loss of about 600 jobs. The company said it will continue to invest in the US and elsewhere, areas that it described as ‘markets of growth.’
Proximagen Group Plc, a 2003 spin-out of King’s College London with an early-stage portfolio of treatments for central nervous system disorders, is to be acquired for up to £356.8 by Upsher-Smith Laboratories Inc of the US.
Tissue Regenix Plc of the UK said that a preclinical study of its tissue regeneration technology showed a better performance than a competitor bovine-derived matrix. The study results were published in the open-access journal, PLoS.
Newron Pharmaceuticals SpA of Italy is to acquire NeuroNova AB, a privately-owned Swedish company that specialises in neurogenesis and which has early-stage compounds for Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
A preclinical drug combination treatment that is being positioned to treat dyskinesia has received €1.3 million in new funding from two Danish investment groups, SEED Capital and Novo Seeds, a unit of the Novo Nordisk Foundation.
Pharming Group NV of the Netherlands said that it has engaged two investment banks to help it explore strategic options that could lead to a merger, an equity investment or a sale. The company expects to issue an update in the third quarter.
Sanofi SA has announced regulatory filings in both the US and Europe for alemtuzumab (Lemtrada) to treat relapsing multiple sclerosis. The monoclonal antibody is already approved in the US for second-line CLL and trades as Campath.